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The dangers of aspirin use in children and young teenagers are well 
documented. In severely ill young children, aspirin can cause or 
exacerbate electrolyte and metabolic derangements as a result of the 
narrow dosage window between therapeutic and toxic effects.1-3 In 
industrialised countries, aspirin is not recommended in paediatric 
practice except for approved therapeutic purposes such as Kawasaki 
disease, because of its association with Reye’s syndrome (RS)3 and 
the availability of equally effective antipyretic agents. Regulatory 
authorities in the UK, the USA and other industrialised countries 
have required warnings on all aspirin-containing preparations about 
their use in children and teenagers since the 1980s.4,5
Our study was prompted by a case of severe aspirin poisoning in 
an infant whose mother had unknowingly administered salicylate 
to her baby in a traditional medicine. This case is described and 
the following questions are addressed: (i) How many children were 
admitted to our hospital over a defined period with evidence of 
salicylate ingestion? (ii) Why was the salicylate given? (iii) Was the 
salicylate administered as over-the-counter (OTC) aspirin or other 
types of salicylate, or was it a component of traditional medicines? 
(iv) What were the morbidity and mortality rates of this group? (v) 
What are the clinical and public health implications of our findings?
Index case
A previously well 7-week-old male infant was admitted to Red Cross 
War Memorial Children’s Hospital (RCH) with a 4-day history of 
poor feeding, cough and progressively rapid respiration. His mother 
had consulted a traditional healer who prescribed a liquid herbal 
mixture. This was given for 3 days prior to admission, but the 
infant’s condition deteriorated. No other medications were reported. 
On admission the child was shocked and encephalopathic with 
fever, pallor, marked jaundice, and an acidotic breathing pattern. 
Admission investigations revealed hypoglycaemia, anaemia and 
urinary tract infection. Escherichia coli was later cultured from an 
admission urine specimen.
His mother brought the herbal mixture for analysis. It was in 
a clear unlabelled Coca Cola bottle and was green with a dense 
white sediment comprising 20 - 25% of the volume. A qualitative 
assessment of the salicylate content of the medicine indicated a 2+ 
level of salicylate. Independent analysis by a forensic laboratory 
confirmed the presence of salicylic acid. Salicylate was also detected 
in the patient’s urine. The patient responded rapidly to treatment and 
was discharged well after 2 weeks with a final diagnosis of urinary 
tract infection complicated by salicylate poisoning.
Methods 
Review of laboratory and clinical records
Clinical chemistry laboratory records between January 2006 and June 
2007 were reviewed to identify all patients for whom blood salicylate 
levels had been requested. Those with a detectable level (defined 
by the hospital laboratory as 0.1 mmol/l) were further selected for 
case note review. A case was defined as any child presenting to 
RCH between January 2006 and June 2007 with a detectable blood 
salicylate level. Plasma salicylate was measured by fluorescence 
polarisation immunoassay technology (Abbott Laboratories). 
Information gathered on the cases is summarised in Table I. Patients 
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taking aspirin for approved therapeutic reasons and having a blood 
level measured for monitoring purposes were excluded.
Poisons unit data
As a check on the completeness of case ascertainment, the poisons 
unit at RCH was asked to provide data on trends in discharges 
and deaths due to salicylate poisoning between January 2004 and 
December 2008. Cases were included on the unit’s database if 
there had been a clinical diagnosis of salicylate poisoning based 
on a history of ingestion and suggestive clinical and laboratory 
features; confirmation by a documented blood salicylate level was 
not required.
Patient data handling
Data from laboratory records and case notes were anonymised, 
transcribed onto a study proforma and entered on an Excel 
spreadsheet. Each data field recorded whether that particular item 
was present, negative or missing. Permission to undertake the study 
was obtained from the University of Cape Town Ethics Committee, 
the Medical Superintendent, the Laboratory Director and the Director 
of the Poisons Unit at RCH.
Results 
Laboratory and clinical record review
Salicylate levels were requested for a total of 156 patients over the 
18-month review period: 25 had detectable levels, but case notes were 
unavailable for 5, leaving 20 available for review. The patients’ ages 
ranged between 3 days and 6 years (median 8.5 months); 9 were aged 
under 6 months. There were 13 males and 7 females. Duration of 
admission ranged between 1 and 56 days (mean 15.7, median 10.5). 
Two patients were hospitalised for 2 months and 9 were admitted to 
the intensive care unit.
Ethnic and social background. Fifteen of the 20 patients’ carers 
were Xhosa speaking, 1 was Afrikaans speaking and 1 was English 
speaking; this detail was not recorded in 3 cases. Social grading 
was available for 18 patients and was recorded as ‘H1’ in all 18. 
This compares with a prevalence of 77.7% of H1 grading among all 
patients seen in the emergency unit between January 2005 and June 
2006, and of 68.9% among all patients admitted to acute paediatric 
general medicine in this period. H1 is the lowest category and equates 
to a family income <R4 800 per month (as stated at registration). The 
geographical distribution of most of the patients’ homes reflected that 
of the poorest parts of Cape Town. The type of housing was recorded 
for 15 patients: 9 lived in shacks, 5 in a brick-built flat or house and 
1 in a hostel.
Pre-admission clinical histories. The duration of illness, where 
recorded (N=15), ranged from 1 day to 2 months (median 7 days). 
The presence or absence of fever as a symptom in the history was 
recorded for 8 cases; it was present in 6 of these. Gastro-intestinal 
symptoms and/or respiratory symptoms were reported in 10 and 
13 patients, respectively. Neurological symptoms were reported 
in 3 patients, of whom all had had seizures and one had also lost 
consciousness; one of these patients had had a closed head injury. 
One patient, otherwise well, presented with acute urticaria.
Overall pre-admission medications (Table II). A total of 16 of 
the 20 patients had a history of receiving medication: in 9 cases this 
was a pharmaceutical (8 being aspirin-containing preparations), 
and in 5 it was a traditional medicine. Two patients had been given 
both; the pharmaceuticals both contained aspirin. The reasons for 
giving preadmission medication were recorded for 10 cases; fever 
was the reason in only 4 cases. Other reasons included diarrhoea, 
cough, ear discharge, fits and ‘fast breathing’. There was no clear 
difference between reasons for using traditional as opposed to OTC 
medications. In 1 case the administration of traditional medicines 
was initially denied by the mother and only elicited on further 
questioning the day after admission. Information on the source of 
these medicines was only provided for 1 case; it was a traditional 
healer.
Clinical features on admission. Although clinical data were 
often incomplete, all patients except one were extremely ill, with 
a range of clinical features and patterns: 8 were described as 
shocked and another as ‘acutely ill’; 15 had one or more abnormal 
neurological findings reported (of whom 7 were encephalopathic, 
2 had a decreased level of consciousness, 4 were fitting and 2 had 
meningism); and 10 patients had an acidotic breathing pattern. 
Table II shows the admission diagnoses – gastro-enteritis and sepsis 
predominated.
Laboratory findings. Table III summarises relevant data. Only 
2 patients out of 12 who had a blood glucose measurement were 
hypoglycaemic; 6 children were hyponatraemic, 4 hypernatraemic, 
and 4 hypokalaemic. The urea was raised in 6, with urea/creatinine 
ratios suggesting a prerenal picture. Liver function was abnormal 
in 9 of 12 patients tested, but most cases were mild and in keeping 
with multisystem effects of sepsis in small infants; one of these had a 
confirmed diagnosis of hepatitis A. The plasma ammonia level was 
abnormal in 5 of 7 patients in whom it was measured.
Twelve of the patients were acidotic and 1 was alkalotic; of those 
who had normal pH values, an additional 4 had base excess values 
outside normal reference range, indicating compensated metabolic 
acidosis. Only 2 patients’ salicylate levels fell into the toxic range 
defined by the laboratory (>2.2 mmol/l). However, for most of the 12 
cases in which the information was recorded, the measurement was 
not undertaken until many hours after ingestion.
The reasons for requesting a salicylate level were recorded for 
17 patients. The commonest (8 cases) was a history of ingestion 
of aspirin; in 3 others it was prompted by a history of ingestion of 
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Table I. Information obtained from case notes review
•   Date of and age at admission 
•    History and clinical features at presentation, including details 
of all pre-admission medications, whether prescribed, OTC or 
traditional; the symptoms for which the medication was given
•    Pre-admission medication details including brand names, 
generic names; presentation; route of application or 
administration; dosages; if OTC, where purchased; if 
traditional, any description including its container and any 
labelling
•   Any available social history
•    Reason for requesting salicylate level; whether this was done on 
admission or later
•   Preliminary diagnosis/es; final diagnosis
•    Simple clinical measures of illness severity: whether the patient 
was admitted to ICU; duration of hospital stay; outcome
•    Laboratory markers on admission: blood glucose, full blood 
count, blood gases, urea, electrolytes, liver function tests
•    Actual blood salicylate level(s), both on admission and later 
where undertaken
•    If a traditional medicine was suspected as the vehicle for the 
salicylate, whether it was investigated for aspirin or any other 
natural or pharmaceutical content and the findings
825
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Table II. Pre-admission medication and diagnostic details
Case No. Age Details of OTC medication Traditional medicine Admission diagnosis Final diagnosis
1 8 mo. Disprin 500 mg × 2 N/R Hyperammonaemic 
encephalopathy
Possible Reye’s syndrome, 
possible mitochondrial 
disorder
2 3 d Disprin ½ tab ( strength not 
known) given 2 days before 
admission
Denied Salicylate poisoning/
metabolic acidosis ?cause
Reye’s syndrome (Δ at 
autopsy), possible LCHAD
3* 3 yrs  
10 mo.
Subdural haematoma Subdural haematoma
4 2 mo. Disprin ½ tab (strength not 
known)
Given 2 weeks before 
admission
Failure to thrive, 
pneumonia, renal failure, 
anaemia
Bilateral dysplastic kidneys, 
rickets, anaemia
5 4 mo. Aspirin (type not specified)  
300 mg tab given in small 
pieces over 2 days
Denied Gastro-enteritis, sepsis, 
aspirin ingestion, ?HIV
HIV +ve, sepsis, chronic CMV 
gastritis
6 6 mo. Disprin ¼ tab (strength not 
known)
Denied N/R N/R, died
7 11 mo. Denied On and off for week 
before admission given 
orally and rectally
Chronic gastro-enteritis, 
?septic shock, toxic 
encephalopathy
N/R, died
8 9 mo. Denied On day of admission Gastro-enteritis, 
?salicylate poisoning
E. coli UTI
9 1 wk Disprin ¼ tab (strength not 
known) 
Dissolved in water, given 6 h 
before admission
Denied Gastro-enteritis/
sepsis/inborn error of 
metabolism
Gastro-enteritis and sepsis
10 6 wks Denied Given 5 days before 
admission
Gastro-enteritis/sepsis Herbal intoxication, 
pneumonia, E. coli UTI, 
gastro-enteritis
11 11 mo. Disprin 1 tab (strength not 
known) × 2 days
Given before seeing GP who 
also prescribed Panado
Denied Liver dysfunction, 
?sepsis, ?drug induced
Hepatitis A 
(IgM +ve)
12* 2 mo. Sepsis Salicylate poisoning, sepsis, 
gastro-enteritis
13 3 mo. Denied ‘Syrup mixture’ day of 
admission given orally
?HIV, gastro-enteritis, 
pneumonia
HIV+ve, LRTI (?PJP), gastro-
enteritis
14 9 mo. Panado (no details) given at day 
hospital before referral
N/R Sepsis, hypovolaemic 
shock, ?meningitis
Gastro-enteritis, shock with 
secondary hypoxic brain 
injury, evolving cerebral palsy
15 5 d Compral tab (‘small piece’) 3 
days before admission
‘Boereraat’ medicine Acute renal failure, 
sepsis, salicylate 
poisoning
Liver failure, sepsis, ruptured 
stomach of unknown cause 
Died
16* 2 yrs  
6 mo.
?Meningitis TB meningitis
17 2 yrs  
3 mo.
Aspirin tab (no details)
Denied on admission, history 
given later
Denied Gastro-enteritis, 
meningitis, liver failure
E. coli UTI, encephalopathy, 
sepsis
18 14 mo. Denied ‘Dutch medicine’ for 6 
weeks
? Toxins, meningitis Dysentery
19 6 yrs Disprin 1 tab (?150 mg) Denied Urticaria Urticaria (aspirin-induced in 
an asthmatic)
20* 3 yrs 
10 mo.
Gastro-enteritis Sepsis and salicylate poisoning
21(PU) 3 yrs ‘Some’ aspirin and 
antihistamine tablets on day of 
admission
N/R Aspirin ingestion Aspirin ingestion
*Cases for whom there was no information on pre-admission medications in the records.   
N/R = not recorded; LCHAD = long-chain acyl CoA dehydrogenase deficiency; CMV = cytomegalovirus; UTI = urinary tract infection; LRTI = lower respiratory tract infection; PJP = Pneumo- 
cystis jiroveci pneumonia; PU = poisons unit case; Δ = diagnosis.
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traditional medicines. For the remaining 6 patients it was because of 
clinical features on admission such as altered consciousness, acidotic 
breathing or acidosis not in keeping with the level of dehydration. It 
subsequently emerged that 4 of these 6 had a history of ingestion of 
aspirin or traditional medicine or both.
Outcome
Information on final diagnosis was available for 19 patients (Table 
II); 4 died and 3 survived with severe brain injury resulting in 
spastic quadriplegia with global delays. No significant sequelae 
were recorded at discharge or follow-up for the remaining 12, 
although 7 failed to attend follow-up appointments. The 2 patients 
with significantly elevated plasma ammonia levels (Table III) had 
a discharge diagnosis of probable or possible RS. The first, who 
survived with brain injury, was subsequently suspected, on the basis 
of a urinary organic acid profile, to have a mitochondrial disorder; 
the other, who died, had a urinary organic acid profile suggestive of 
long-chain acyl CoA dehydrogenase deficiency. Salicylate poisoning 
was the recorded final diagnosis in only 2 patients. In none was 
there a record of any discussions with the caregiver concerning the 
administration of either OTC or traditional medicines.
Poisons unit data
Six patients with salicylate poisoning were recorded between January 
2004 and December 2008. Blood salicylate levels had been measured 
in 4. Only 1 extra case in the relevant time period was identified 
which had not been ascertained by our review of laboratory records, 
because a blood salicylate level had not been measured. In contrast, 
none of the cases ascertained in the laboratory review appeared on 
the poisons unit database.
Discussion
During the 18-month study period at least 21 children were admitted 
to RCH having been administered pre-admission aspirin which 
had not been prescribed for therapeutic reasons. This number is a 
minimum because there were 5 more with missing case notes and 
other cases may not have had a salicylate level measured. The most 
prevalent source was OTC aspirin, but some patients had reportedly 
only been given traditional medicines. Only in our index case, 
however, was there laboratory proof that the traditional medicine 
was the source. There was no evidence of toxic exposure to forms of 
salicylate other than aspirin. The medication had been given for a 
wide range of symptoms. All except 2 of the patients were seriously 
ill, 4 died and 3 were left with severe brain injury.
Although only 2 of our cases had admission salicylate levels above 
the 2.2 mmol/l that indicates toxicity by the laboratory reference 
range, this may not represent the true extent of the toxic effects of 
aspirin on the patients’ illnesses. We cannot tell to what extent the 
salicylate affected outcome, but the literature suggests that it was 
likely to have been deleterious.
Buchanan reviewed his experience at Chris Hani Baragwanath 
Hospital of the effects of aspirin given to infants and young children 
with severe illness (in contrast with accidental overdose in a healthy 
subject).1 He emphasised that blood levels are an unreliable guide to 
toxicity, because the extent of the acid-base disturbance caused both 
by the aspirin and by the underlying illness will affect the amount 
of salicylate entering the cerebrospinal fluid (CSF) and brain. In 
children aged 1 - 4 years a metabolic acidosis (which favours such 
transfer) can be expected with aspirin toxicity; the respiratory 
alkalosis seen in adults does not develop until after the age of 12 
years. Buchanan concluded that toxic levels of blood salicylate in 
young children can be as low as 15 mg/100 ml (1.09 mmol/l). In 
our study nearly half the patients were less than 6 months old and 
the oldest was 6 years old; there were 2 babies less than a week old. 
Metabolic acidosis was a consistent finding in the majority, even if 
partially compensated in some. The fact that in three-quarters of 
the patients who had liver function tests these were abnormal may 
reflect not only the underlying illness but also the effects of aspirin, 
which can cause raised hepatic enzymes.6 Owing to their young age, 
and in most cases severe systemic illness with associated metabolic 
disturbance, these children were therefore particularly vulnerable to 
the toxic effects of aspirin.
A study of the age-related pharmacokinetics of aspirin showed 
that infants have much lower elimination rates than 10 - 15-year-olds.7 
Another important consideration is therefore the interval between 
ingestion and first measurement of salicylate level. For nearly half of 
our patients the time of ingestion was unknown or unrecorded; among 
the rest in only 3 cases was it probably less than 24 hours, and in 1 case 
the measurement was done at least 6 days later. Done8 showed that this 
is the most important variable affecting the relationship between the 
level and clinical signs of toxicity in patients with accidental aspirin 
poisoning. He developed a nomogram for retrospectively estimating 
the highest post-ingestion level based on a series of previously well 
subjects – the effects of age and illness were still unknown.
We therefore hypothesise that, regardless of observed blood levels, 
several patients in our series may have suffered salicylate toxicity which 
probably exacerbated their underlying illness. A study of children in 
Kenya,2 admitted with initial diagnoses of severe malaria, drew the 
same conclusion; 90% had detectable salicylate, some at toxic levels. 
The authors suggest that in some children salicylate poisoning may 
cause or contribute to the development of severe metabolic acidosis 
and hypoglycaemia, complications of malaria associated with high 
mortality. The biological plausibility of this clinical observation has 
subsequently been supported on theoretical grounds.9
The dangers of aspirin in African children described above1,2 are 
not a major issue in industrialised countries where, because of the 
association with RS, aspirin is no longer recommended for children.10 
A UK national guideline on the management of fever in children 
recommended as antipyretics only paracetamol and ibuprofen.11 In 
the UK, labelling legislation passed in 1986 was modified in 2003, 
stating that aspirin should not be used in children under 16 years 
except on the advice of a doctor and that all OTC aspirin-containing 
preparations should carry warnings on the external packaging and 
on the patient information leaflet inside.4 Similar legislation has been 
promulgated in the USA.5 Following these measures, the incidence of 
RS declined dramatically in both countries.12,13
A diagnosis of RS was considered in 2 of our patients (Table II, 
cases 1 and 2) on the basis of liver function tests and, in case 2, on 
autopsy findings, but in both subsequent investigation suggested that 
a ‘Reye-like’ inherited metabolic disorder was more probable.14 Also, 
in one of these patients the salicylate level was still at 0.93 mmol/l 
on day 6 after admission, so it may have been at toxic levels earlier 
in the illness.8 Neither patient had the clinical features of ‘classic’ 
aspirin-associated RS, which rarely if ever occurs in young infants 
(our cases were aged 8 months and 3 days, respectively) and should 
only be diagnosed after other conditions have been excluded. Patients 
with RS-like features in this age group should first be exhaustively 
investigated for one of the many inherited metabolic disorders that 
mimic the condition before diagnosing RS.14
Our findings led us to speculate whether the use of OTC aspirin in 
children may be a problem in our area and elsewhere in South Africa, 
at least in poorer communities. Comorbidity caused by salicylate 
toxicity may be under-recognised. Among infants and children 
admitted to a hospital in the Eastern Cape with a diagnosis of ‘herbal 
intoxication’, 13.5% were recorded on admission to have acidotic 
breathing; 50% had respiratory distress. Nearly half died, mostly 
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those aged <6 months. The investigation or possibility of salicylate 
toxicity was not reported or discussed.15
Our study shows that, in contrast to industrialised populations, 
some young children in the poorer areas of Cape Town are receiving 
aspirin. In addition to its adverse clinical effects, this raises several 
issues of public health significance. First, do the hazards associated 
with aspirin and its low cost justify its continued easy availability for 
symptomatic relief in childhood illnesses in South Africa? Second, 
what are the extent and effect of pharmaceuticals added to traditional 
medicines? Third, are parents sufficiently informed about the risks 
associated with aspirin use in their children, in OTC and traditional 
medicines? We will report elsewhere the information about aspirin 
use provided on packaging and package inserts, both of which 
are regulated by the Medicines Control Council. In resource-poor 
countries with low literacy levels, providing accessible information 
about the hazards of medicines will always be a challenge.
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KEY POINTS
•    Salicylate toxicity should be considered in all paediatric patients 
with metabolic acidosis which is unexplained or out of keeping 
with the severity of their acute illness. 
•    A careful history should be taken as to when the last exposure 
to aspirin/salicylate/traditional medicine occurred and blood 
salicylate levels interpreted accordingly.
•    Reye’s syndrome should only be diagnosed after detailed 
investigation to exclude the inherited metabolic disorders 
which mimic it, especially in young children and infants.
•    The risks of use of aspirin in children for symptomatic relief 
in feverish illnesses should be explained to caregivers. They 
should also be warned that traditional medicine may contain 
aspirin as well as other potentially harmful substances.
•    In contrast to many other countries, South African parents, 
especially those in the poorer sections of society, may be 
unaware of the dangers of aspirin. This should be of concern to 
the regulatory authorities.
•    Case ascertainment for epidemiological surveillance of aspirin 
poisoning should include laboratory record review.
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